Royce & Associates LP Has $3.07 Million Holdings in Repligen Co. (RGEN)
Royce & Associates LP grew its position in shares of Repligen Co. (NASDAQ:RGEN) by 14.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 80,149 shares of the biotechnology company’s stock after purchasing an additional 10,149 shares during the period. Royce & Associates LP owned 0.18% of Repligen worth $3,071,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Repligen during the 2nd quarter worth about $120,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Repligen during the 2nd quarter worth about $123,000. Victory Capital Management Inc. boosted its stake in shares of Repligen by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 601 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Repligen during the 3rd quarter worth about $180,000. Finally, Pinebridge Investments L.P. boosted its stake in shares of Repligen by 1.7% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 76 shares during the last quarter. 82.50% of the stock is currently owned by institutional investors.
RGEN has been the topic of several recent analyst reports. Jefferies Group reiterated a “hold” rating and set a $40.00 price objective on shares of Repligen in a report on Thursday, September 14th. Stephens reiterated an “overweight” rating and set a $50.00 price objective on shares of Repligen in a report on Tuesday, September 26th. First Analysis upgraded shares of Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective on the stock in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Thursday, October 5th. Finally, CL King started coverage on shares of Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Repligen currently has an average rating of “Buy” and an average target price of $44.38.
Shares of Repligen Co. (RGEN) opened at $35.33 on Wednesday. The stock has a market cap of $1,571.84, a P/E ratio of 62.21, a PEG ratio of 2.35 and a beta of 1.04. Repligen Co. has a 12 month low of $28.48 and a 12 month high of $46.81.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The business’s quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 earnings per share. analysts expect that Repligen Co. will post 0.61 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Royce & Associates LP Has $3.07 Million Holdings in Repligen Co. (RGEN)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/royce-associates-lp-has-3-07-million-holdings-in-repligen-co-rgen/1773890.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.